Acelyrin price target lowered to $6 from $8 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Acelyrin (SLRN) to $6 from $8 and keeps a Neutral rating on the shares. During the call yesterday, the company noted it sees thyroid eye disease as a $2B opportunity for the standard of care therapy, the analyst tells investors in a research note. Therefore, the firm lowered its global peak sales estimate to $2.5B from $2.8B. It believes some investors may also be disappointed by the less frequent dosing regimen selected for Phase 3.